RhumbLine Advisers
OCEA

RhumbLine Advisers’s Ocean Biomedical, Inc. Common Stock OCEA Stock Holding History

RhumbLine Advisers’s Portfolio OCEA Stock Details OCEA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-876
Closed -$1.07K – 4358
2024
Q2 		$1.07K Sell
876
-8,901
-91% -$15.2K ﹤0.01% 4239
2024
Q1 		$37K Sell
9,777
-1,381
-12% -$2.6K ﹤0.01% 3688
2023
Q4 		$7.36K Buy
11,158
+1,470
+15% +$2.02K ﹤0.01% 3917
2023
Q3 		$37.8K Buy
9,688
+945
+11% +$4.34K ﹤0.01% 3701
2023
Q2 		$52.5K Buy
+8,743
New +$51.3K ﹤0.01% 3670

Other funds holding OCEA

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

RhumbLine Advisers's OCEA Position: Q3 2024 in Review

RhumbLine Advisers sold out of Ocean Biomedical, Inc. Common Stock (OCEA) in Q3 2024, closing a stake of 876 shares — an estimated $1.07K sold.

RhumbLine Advisers first reported a position in OCEA in Q2 2023 and held it in 5 quarters. The position peaked at $52.5K in Q2 2023. 21 funds tracked by Wall St. Rank hold OCEA as of Q3 2024.

  • RhumbLine Advisers reported no remaining Ocean Biomedical, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 876 Ocean Biomedical, Inc. Common Stock shares in Q3 2024, an estimated $1.07K.
  • RhumbLine Advisers first reported a position in Ocean Biomedical, Inc. Common Stock in Q2 2023 and held it in 5 quarters.
  • RhumbLine Advisers's Ocean Biomedical, Inc. Common Stock position peaked at $52.5K in Q2 2023.
  • 21 funds tracked by Wall St. Rank held Ocean Biomedical, Inc. Common Stock as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.